Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

Blood Cancer J. 2021 Feb 16;11(2):35. doi: 10.1038/s41408-021-00431-5.


Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney disease, or death within 12 months of LOT initiation. Annual HRU and costs in the first three LOTs (L1-L3) were compared for patients with versus without disease progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in L1-L3 were $18,359, $87,055, and $71,917, respectively, among LOTs initiated between 2006 and 2018. In LOTs initiated between 2013 and 2018, the figures were $46,024, $100,329, and $101,942 in L1-L3, respectively. The economic burden of disease progression is substantial in this population of MM patients who underwent SCT and received systemic anti-myeloma therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Cost of Illness*
  • Disease Progression
  • Female
  • Health Care Costs
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / economics*
  • Multiple Myeloma / epidemiology
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy*
  • Retrospective Studies
  • Stem Cell Transplantation / economics
  • United States / epidemiology


  • Antineoplastic Agents